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Dietary supplementation with complex carbohydrates is known to alter the composition 
of gut microbiota, and optimal implementation of the use of these so called “prebiotics” 
could be of great potential in prevention and possibly treatment of obesity and asso-
ciated cardiometabolic and inflammatory diseases via changes in the gut microbiota. 
An alternative to this “microbiocentric view” is the idea that health-promoting effects 
of certain complex carbohydrates reside in the host, and could secondarily affect the 
diversity and abundance of gut microbiota. To circumvent this potential interpretational 
problem, we aimed at providing an overview about whether and how dietary supple-
mentation of different complex carbohydrates changes the gut microbiome in healthy 
non-obese individuals. We then reviewed whether the reported changes in gut bacterial 
members found to be established by complex carbohydrates would benefit or harm the 
cardiometabolic and immunological health of the host taking into account the alterations 
in the microbiome composition and abundance known to be associated with obesity 
and its associated disorders. By combining these research areas, we aimed to give 
a better insight into the potential of (foods containing) complex carbohydrates in the 
treatment and prevention of above-mentioned diseases. We conclude that supplemental 
complex carbohydrates that increase Bifidobacteria and Lactobacilli, without increasing 
the deleterious Bacteroides, are most likely promoting cardiometabolic and immunolog-
ical health in obese subjects. Because certain complex carbohydrates also affect the 
host’s immunity directly, it is likely that host–microbiome interactions in determination 
of health and disease characteristics are indeed bidirectional. Overall, this review article 
shows that whereas it is relatively clear in which direction supplemental fermentable 
carbohydrates can alter the gut microbiome, the relevance of these changes regarding 
health remains controversial. Future research should take into account the different 
causes of obesity and its adverse health conditions, which in turn have drastic effects on 
the microbiome balance.
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iNTRODUCTiON
It is now well recognized that the bacteria living in our gut 
play an important role in the development and maintenance of 
the innate and adaptive immune system (1, 2) as well as the 
fermentation of low-, or non-digestible dietary carbohydrates 
(3–5). While the human intestinal microbiome is dominated 
by the phyla Bacteroidetes and Firmicutes (representing 
more than 90% of the total bacterial population) and with 
Proteobacteria, Verrucomicrobia, Actinobacteria, Fusobacteria, 
and Cyanobacteria generally being present in minor proportions 
(6), the exact composition can vary widely between individuals. 
Contributing factors to this variation are (1) the host’s genetic 
make-up (7), (2) early-life environmental conditions under 
which the host was born and nourished (i.e., cesarean sec-
tion versus vaginal delivery, breast milk versus infant formula 
feeding, perinatal stress) (8–11), (3) the type and intensity of 
antibiotic treatment the host has undergone (12), and (4) the 
microbial composition that appears to change slowly with age 
(13–15). Whereas the acquired microbial abundance and diver-
sity was initially thought to be relatively stable and withstand 
sudden perturbations (16, 17), it was found more recently that 
changes in the diet can affect microbial composition after its 
initial establishment (18–20). For diet-driven alterations of gut 
microbial composition particularly the type and proportion of 
complex indigestible carbohydrates that reach the colon turn 
out to be of great importance (18, 19, 21–24). The digestibility 
of dietary carbohydrates depends, among others, on structural 
properties of the carbohydrate, such as the degree of polymeri-
zation (DP) and branching. In general, carbohydrates with a low 
DP can rapidly be absorbed or digested in the small intestine. 
The larger oligosaccharides and polysaccharides have a variety 
of branching and polymerizations, which render them more dif-
ficult for host enzymes in the small intestine to be hydrolyzed 
(25). Carbohydrates with higher DP’s will, therefore, enter the 
large bowel, where they will be fermented by bacteria, which are 
highest in abundance in this part of the gastrointestinal tract 
(3, 4). Another factor for digestibility of polysaccharides is of 
course whether or not the digestive enzymes for specific cleav-
ages are present in the digestive tract of an animal. For example, 
humans do not have the enzymes required to cleave the relevant 
linkages in, e.g., cellulose and beta-glucan, which render them 
indigestible and therefore reach the bowel where they can be 
fermented.
Besides playing a role in fermentation and immune func-
tioning, the diversity and abundance of gut microbiota also 
plays a role in regulation of body weight and energy balance 
(26–28). This notion started with the discovery of Turnbaugh 
and colleagues in 2006 showing that transplantation of gut 
microbiota of genetically obese ob/ob mice into the gut of 
germ-free mice resulted in greater weight gain of the receiving 
animals than animals that received the microbiota of their lean 
counterparts (29). Comparable studies have since then been 
done, all adding to the conclusion that obesity risk, as well as 
related cardiometabolic and inflammatory derangements may 
rely, at least in part, on gut microbiota (30–34). Because of the 
apparent fact that the relative abundance and diversity of gut 
microbiota is related to the host’s health and/or disease status 
(20, 35), the possibility to affect the composition of intestinal 
microbiota by complex indigestible carbohydrates—so-called 
“prebiotics”—and subsequently improve the health of the host 
(36) has gained a lot of interest over the past few years.
Several randomized-controlled studies have been conducted 
over the years to elucidate the effects of supplementation 
of indigestible carbohydrates on several health indices in 
(1) healthy volunteers (37, 38), (2) subjects diagnosed with 
metabolic syndrome (MetS), type-2 diabetes mellitus (T2DM), 
cardiovascular disease (CVD), and/or inflammatory bowel 
disease (IBD), and (3) subjects at risk of having these diseases 
because of the fact that they are overweight or obese (39–43). It 
is difficult to evaluate the role of the microbiome in the reported 
health effect of supplemental carbohydrates. It was for example 
recently shown that a polymer of fructose molecules (i.e., 
β2→1-fructan) has a direct modulatory effects on immunity, 
which in turn affects the colonizing microbiota. Of note, the 
effects of the tested carbohydrates were dependent on the chain 
length of the β2→1-fructans type polymer (44). These results 
suggest that health-promoting effects of certain complex carbo-
hydrates are actually residing in the host, and could secondarily 
affect the diversity and abundance of gut microbiota, thereby 
providing an alternative to the current “microbiocentric” view 
on health and disease. For this reason, we aimed at providing 
an overview, based on human trials, about whether and how 
dietary supplementation of different (potentially prebiotic) car-
bohydrates changes the gut microbiome in healthy individuals. 
We then reviewed whether the reported changes in gut bacterial 
members found to be established by prebiotic carbohydrates 
would benefit or harm the host’s health taking into account 
the alterations in the microbiome composition and abundance 
known to be associated with obesity, CVD, T2DM, and/or IBD. 
By combining these research areas, we aimed to give a better 
insight into the potential of (foods containing) prebiotic carbo-
hydrates in the treatment and prevention of above-mentioned 
diseases.
HOw CAN PReBiOTiCS AFFeCT THe 
HOST HeALTH THROUGH GUT 
MiCROBiOTA
Before discussing the studies investigating the health effects 
of supplemental carbohydrate on the microbiome, we first 
discuss a few potential mechanisms how these health effects 
can be substantiated. Microbial fermentation can convert the 
carbohydrate residues in, among others, short-chain fatty acids 
(SCFAs). These SCFAs comprise acetate, propionate, and butyrate 
(5) and can account for up to 10% of the energy absorbed from 
the diet, benefiting the microbiota as well as the host. The SCFAs 
acetate and propionate are mainly produced by Bacteroidetes, 
and butyrate is the primary product of the Firmicutes bacteria 
(45, 46). Besides the delivery of extra fuels from fermentation 
of complex carbohydrates that escape digestion, the host also 
benefits from these microbial fuels in other ways. For example, 
through their effects on gastric motility and intestinal transit 
TABLe 1 | Overview of the major dietary carbohydrates.
Class (DP) Subgroup Principal components Physiology Possible source
Sugars (1–2) Monosaccharides Glucose, fructose, galactose Absorbed Fruits
Disaccharides Sucrose, maltose, trehalose Absorbed Sugar cane/beets
Lactose Absorbed/fermented Dairy






Maltodextrins Digested/fermented Glucose syrups
Non-α-glucan 
oligosaccharides
Raffinose, stachyose Fermented Beans, peas, soya
Fructo-oligosaccharides, galacto-oligosaccharides Enzymatic synthesis
Polydextrose Synthetic
Inulin Wheat, onion, banana
Polysaccharides (≥10) Starch (α-glucans) Amylose, amylopectin, modified starches Digested/fermented Potatoes
Non-starch 
polysaccharides
Cellulose, hemicellulose, pectin, arabinoxylans, β-glucan, 
glucomannans, plant gums and mucilages, hydrocolloids, 
soluble corn fiber
Fermented Cell wall plant cells (fruits/
vegetables)
DP, degree of polymerization or number of monomeric (single sugar) units.
Table based on Cummings and Stephan (25), Cummings et al. (62), and Roberfroid (63).
3
Vinke et al. Prebiotics, Microbiome and Host Health
Frontiers in Nutrition | www.frontiersin.org July 2017 | Volume 4 | Article 34
stimulation, SCFAs stimulate serotonin release as reported in an 
in vitro colonic mucosal system (47). Locally butyrate functions as 
an important energy source for colonocytes, and this interaction 
contributes to a reduction in the risk of colorectal cancer (4, 48). 
Butyrate also affects fuel fluxes and energy balance by stimulat-
ing leptin and glucagon-like peptide 1 amide (49). Butyrate has 
even been reported to elicit antidepressant effects in the mouse 
(50) and to stimulate social behavior and facilitating long-term 
memory consolidation and neuroprotection/regeneration (51, 
52). Importantly, SCFAs appear to also reduce the risk of CVD, 
IBD, T2DM, and diet-induced obesity (4). The processes under-
lying the aforementioned effects of SCFAs are subject to intense 
investigation, and several interesting leads have been elucidated.
Besides fermenting poorly or indigestible carbohydrates, 
resulting in among others increased levels of SCFAs, the gut 
microbiota can also modulate the uptake and deposition of 
dietary lipids by affecting the activity of the lipoprotein lipase in 
adipose tissues, an enzyme that promotes fatty acid uptake into 
adipocytes (33), and by affecting the synthesis of colipases, which 
are involved in the hydrolysis of dietary lipids (53). Endocrine 
(cortisol, gut hormones), immune (cytokines), and neural (vagus 
and enteric nervous system) routes have been suggested to play 
a role in the communication between gut microbiota (e.g., via 
the metabolites it produces upon digestion of prebiotics) and 
peripheral organs and the brain (54–57). Although underlying 
mechanisms are far from understood, it is likely that the commu-
nication between the central nervous system and gut microbiota 
functions bidirectionally (54, 57–59).
ASSeSSiNG eFFeCTS OF PReBiOTiCS iN 
HeALTHY SUBJeCTS AND ReLevANCe 
FOR THOSe wiTH CARDiOMeTABOLiC/
iNFLAMMATORY DiSeASeS AND 
OBeSiTY
Food ingredients with prebiotic properties are often oligosac-
charides and polysaccharides (Table  1) (25, 60–63), such as 
inulins, pectins, and β-glucan compounds. Most prebiotics 
are already included in the diet as they are naturally present 
in several types of food [e.g., legumes, wheat, rye, and onions 
(64, 65)], and are, therefore, considered to be part of a diet that 
contributes to the maintenance of sustainable health (66–68). 
Of note, although usually ignored in research reports, the 
(excessive) use of prebiotics could eventually lead to undesirable 
effects like excessive flatus, borborygmi, abdominal pain, and 
diarrhea (69, 70). To assess the effect of dietary supplemental 
(potentially prebiotic) carbohydrates on gut microbiota compo-
sition, a literature search was performed in PubMed and Google 
Scholar, as shown in Table 2. The initial literature search was 
performed in January 2016 and was revised in January 2017. 
The search term always included “gut microbiota OR micro-
biota,” which was then combined with the terms “composition,” 
“prebiotic,” and “polysaccharides” or oligosaccharides. Search 
results were then screened for clinical trials in healthy humans, 
which eventually narrowed down the results to 20 clinical stud-
ies. All studies included daily supplementation of (potentially 
prebiotic) carbohydrates for a minimum of 2 weeks and for a 
maximum of 10 weeks. We first subdivided these trails on the 
basis of the type of supplemental carbohydrates that were used 
in the different trials, and we then assessed the direction of 
change in the different bacterial phyla and/or genera. All studies 
used freshly voided fecal samples, and subsequently, a variety of 
methodologies were used to determine microbiota composition, 
including Florescent in situ hybridization (FISH), quantitative 
(q)PCR, 16S ribosomal RNA sequencing, and whole-genome 
shotgun sequencing.
Traditionally, the composition of the microbiota was ana-
lyzed by using culturing techniques, which select for specific 
bacterial populations based on their metabolic requirements. 
These techniques, however, are clearly only applicable to the 
culturable fraction of the members (i.e., which is only true for 
about 20–50%) and has limited resolution (6, 71, 72). Culture-
independent techniques that are frequently used nowadays 
include 16S ribosomal RNA-based techniques such as qPCR 
and illumina (deep) sequencing. Last, whole-genome shotgun 
TABLe 2 | Overview of search terms and the number of hits in PubMed.
Search term Total Clinical trials
((gut microbiota) OR microbiota) AND carbohydrate 2,465 187
((gut microbiota) OR microbiota) AND prebiotic 1,077 106
((gut microbiota) OR microbiota) AND composition AND 
prebiotic
391 43
((gut microbiota) OR microbiota) AND composition AND 
prebiotic AND polysaccharides
232 36
((gut microbiota) OR microbiota) AND composition AND 
prebiotic AND oligosaccharides
106 18
((gut microbiota) OR microbiota) AND composition AND 
prebiotic AND polysaccharides AND human
190 35
((gut microbiota) OR microbiota) AND composition AND 
prebiotic AND oligosaccharides AND human
79 18
Search terms were combined to find studies assessing the effect of potentially prebiotic 
carbohydrates on gut microbiota composition. Studies referred to in review articles 
published on the topic were also included in some cases. Only studies supplementing 
the diet of healthy individuals were included. Second, the microbiota genera that were 
found to be altered upon carbohydrate supplementation were then further investigated 
in a second literature search in which the name of the genera was combined with the 
search terms “correlation,” “health,” “obesity,” “diabetes,” “inflammation,” “cardio(-) 
metabolic disease,” and “cardio(-)vascular disease.” Again, studies referred to in review 
articles published on the topic were also included in some cases. Here, animal studies 
were included, in addition to human studies, because they can often be instrumental in 
explaining the health effects of the genera in the (sometimes scarce) human studies.
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sequencing does not only sequence a marker gene such as the 
16S ribosomal RNA but also examines the whole-genome in 
which it provides more detailed information about the func-
tional and metabolic potential of the community (71, 72). An 
overview of the trials that were found by using the (combined) 
search terms (Table 2) is presented in Table 3 (24, 64, 73–91). 
We subsequently characterized the effects of the different sup-
plemental carbohydrates per phylum, and for each of them 
discussed the feasibility of treating subjects diagnosed with 
obesity, cardiometabolic, and/or inflammatory diseases with 
any of these prebiotics.
BACtERoidES
Most studies demonstrated an increase in Bacteroides abun-
dance by a variety of supplemental disaccharides, oligosac-
charides, and polysaccharides, with doses ranging between 
2.2 and 45.6 g per day, and duration between 2 and 10 weeks 
of treatment (73, 75, 76). Supplemental carbohydrates that 
reduced Bacteriodes were a very long-chain inulin given in a 
dose of 10 g/day over the course of 3 weeks (84) and soluble 
corn fiber given in a dose of 20 g/day over 4 weeks (89). Some 
studies, however, showed results that may be explained by 
other means than the supplemental carbohydrate per sé. For 
example, the study by Walton et al. (76) used a relatively low 
dose of arabinoxylan-oligosaccharides in bread with potential 
effects on Bacteroides, suggesting that its supplementation has 
a high feasibility for long-term human application. However, 
in that study, the increase in Bacteroides was also observed 
in the control group, presumably due to the higher total 
amount of (complex) carbohydrates present in the diet due 
to the control bread (76). Therefore, it is unknown whether 
arabinoxylan-oligosaccharides specifically are able to increase 
Bacteroides at this dose. The Bacteroides-increasing effect of 
5.5 g per day by the mixture of galacto-oligosaccharides in the 
study by Vulevic et al. (75) was, therefore, more convincing.
If most prebiotics increase Bacteroides abundance (with 
the exception of very long-chain inulin), it is of interest to 
know whether this direction would be either beneficial or 
detrimental for subjects with obesity and cardiometabolic and/
or inflammatory diseases. Studies investigating the association 
between Bacteroides and obesity and cardiometabolic health 
are abundant but highly contradicting (5, 92). Several studies 
have reported changes at the phylum level in relation to obesity, 
with a low abundance of Bacteroidetes relative to the propor-
tion of Firmicutes in obese individuals (93, 94), as well as in 
genetically obese (ob/ob) mice (29, 95). For instance, a study by 
Armougom et al. (96) in 20 normal weight and 20 obese French 
individuals confirmed the decrease in Bacteroidetes abundance 
in obese individuals, accompanied by an increase of the genus 
Lactobacillus, belonging to the phylum Firmicutes. Studies 
by Turnbaugh et al. (97) and Furet et al. (98) only detected a 
reduced representation of Bacteroidetes, like Bacteroides and 
Prevotella, without changes in Firmicutes abundance in obese 
individuals. However, contradicting results were found in a 
study by Schwiertz et al. (99), where in overweight and obese 
subjects the ratio of Firmicutes to Bacteroidetes was increased 
in favor of the Bacteroidetes. Other findings even suggest that 
the proportions of Bacteroidetes and Firmicutes do not have 
a major relation with human obesity at all (100). At the genus 
level, a study investigating gut microbiota in pregnant women 
revealed a positive correlation between BMI before pregnancy 
and the abundance of Bacteroides. The high abundance of 
Bacteroides was also associated with excessive weight gain 
during pregnancy (101). Due to the higher number of studies 
reporting a decrease in Bacteroidetes in obesity, combined with 
the fact that some of these studies used 16S rRNA sequencing, 
which is more accurate than qPCR and FISH used in the con-
tradicting studies, it is more likely that obesity is associated with 
a decrease in Bacteroidetes. However, at this point a causal role 
of Bacteroidetes or of the genus Bacteroides in obesity has not 
been convincingly proven.
One possible explanation for the above-mentioned indecisive 
link between Bacteroides and obesity is that it is not obesity per se, 
but the presence of adverse health conditions that are part of MetS 
that are closely associated with the abundance of Bacteroides. As 
mentioned before, MetS is often seen in obese individuals and is a 
risk factor for the development of cardiometabolic/inflammatory 
diseases (102). In a study by Haro et al. (22) on 239 volunteers of 
which 138 met the criteria for MetS, the relative abundance of 
Bacteroides indeed turned out to be higher in the MetS subjects 
than in subjects without MetS. The study did not report a rela-
tion between Bacteroides abundance and BMI or magnitude of 
obesity. Only a negative relation between waist circumference 
and the relative abundance of Bacteroides thetaiotaomicron was 
observed (R = 0.162, P = 0.022). It must be noted that the non-
MetS group in this trial did not include healthy individuals, but 
individuals with a history of coronary heart disease that were 
involved in another clinical trial at the time (23). Furthermore, 
TABLe 3 | Overview of the studies in which the diet of healthy subjects was supplemented with prebiotic carbohydrates.
Carbohydrate 
group
Supplement Treatment Affected microbiota −/+ Na Analysis Reference



















Bifidobacterium + 32 bTE-FAP/16S rRNA 
gene sequencing
Finegold et al. (64)


















10 g/day—3 weeks Bifidobacterium + 20 qRT-PCR Cloetens et al. (77)
Galacto-oligosaccharides 8 g/day—3 weeks Bifidobacterium + 39 qPCR Walton et al. (78)
Xylooligosachharide 5 g/day—4 weeks Bifidobacterium + 60 qPCR Lecerf et al. (79)









5 g/day—30 days Bifidobacterium + 52 Plate count technique Mitsou et al. (80)




tech.-based 16S rRNA 
sequencing)
Baer et al. (81)















Agave inulin 5.0/7.5 g/ 
day—3 weeks
Actinobacteria + 29 16S Illumina sequencing Holscher et al. (83)
Bifidobacterium +
Desulfovibrio −
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Supplement Treatment Affected microbiota −/+ Na Analysis Reference
Inulin 10 g/day—16 days Bifidobacterium adolescentis + 12 qRT-PCR Ramirez-Farias  
et al. (85)Faecalibacterium prausnitzii +
Inulin/partially hydrolyzed 
guar gum




Soluble corn fiber 6 g/day—2 weeks Bifidobacterium + 24 FISH Costabile et al. (24)
Soluble corn fiber 12 g/day—2 weeks C. histolyticum/ C. perfringens − 24 FISH Costabile et al. (24)





Soluble corn fiber 10 g/day—4 weeks Parabacteroides + 27 16S Illumina sequencing Whisner et al. (89)
Soluble corn fiber 20 g/day—4 weeks Bacteroides − 27 16S Illumina sequencing Whisner et al. (89)
Parabacteroides +
Lachnospira −





The studies investigated the subsequent changes in gut microbiota composition.
aTotal number of volunteers, divided over study groups.
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a higher abundance of Bacteroides has been reported to be associ-
ated with impaired glucose tolerance in T2DM patients as well 
(103). Finally, Bacteroides abundance was higher in individuals 
with several disease characteristics (but not necessarily marked 
as MetS) rendering them more at risk to develop pre-diabetes, 
T2DM, and CVD (104). While there are also studies showing no 
clear link between Bacteroides abundance and cardiometabolic 
diseases (105, 106), the available data on MetS and Bacteriodes 
abundance are exciting enough to emphasize on research inves-
tigating causal mechanisms between the two. It may for instance 
be speculated that obese individuals are more prone to develop 
MetS due to an already existing high abundance in Bacteroides, 
or alternatively, it could be that MetS in the host causes changes 
in Bacteroides abundance bidirectionally.
A pathological feature that is commonly observed in a wide 
range of chronic conditions such as MetS, non-alcoholic fatty 
liver disease, CVD, and T2DM is a persistent low-grade inflam-
matory state, characterized by increased levels of inflammatory 
cytokines (107–110). It is possible that the gut microbial imbal-
ance and the permeability of the intestinal barrier contribute 
to this low-grade systemic inflammation, which may then 
be related to the onset and progression of cardiometabolic 
derangements (111). However, it could also be the other way 
around, being that the state of inflammation is the cause of the 
microbial dysbiosis. Interestingly, also higher abundances of 
Bacteroides species were found in patients with IBD compared 
to healthy individuals (112, 113), suggesting that a disturbance 
of the gut microbial balance in favor of Bacteroides is linked to 
inflammation of the GI tract. IBD is relatively frequently associ-
ated with MetS (114, 115), which adds to the possibility that 
Bacteroides abundance and disturbances in the inflammatory 
system are linked. The direction of this relation is currently 
unclear.
CloStRidium
Clostridium levels were reported to decrease by the supplementa-
tion of 65.2 g of raffinose/stachyose for 2 weeks (74), by 15 g of 
a mixture of inulin and partially hydrolyzed guar gum during a 
3-week supplemental intervention study (86), or by supplemen-
tation with 5  g of α-galacto-oligosaccharides for 2  weeks (91). 
Of the previous studies, the latter has a highest feasibility due 
to the lower dose. Furthermore, it must be noted that the study 
supplementing with a mixture of inulin and partially hydrolized 
guar gum investigated the matter in constipated women, leading 
to an increased transit time wherefore the effect could be different 
in individuals without constipation.
The decrease of Clostridium abundance has been linked to 
decreased severity of T2DM and obesity (101, 105, 116). For 
example, in the studies by Karlsson et al. (105) and Larsen et al. 
(116), lower levels of the genus Clostridium and the class Clostridia, 
respectively, were found in T2DM patients compared to healthy 
controls. In addition, an inverse relation between Clostridium 
genus abundance and high-sensitivity C-reactive protein 
(hs-CRP), an inflammatory marker associated with the risk of 
CVD (26), has been observed (117). This suggests a potentially 
beneficial link between abundance of the Clostridium genus 
and metabolic health. Moreover, the expansion of Clostridia 
species belonging to Clostridium cluster IV and XIVa after the 
conventionalization of germ-free mice coincided with increas-
ing concentrations of SCFAs, such as acetate, propionate, and 
butyrate (118), of which the beneficial effects have been discussed 
before. These latter studies all describe beneficial effects of the 
presence of specific Clostridium species. However, studies report-
ing higher T2DM and CVD risk with lowered Clostridium levels 
are available as well (119, 120). Due to the controversy, it remains 
unclear whether the decrease in Clostridium that could possibly 
TABLe 3 | Continued
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be established by the consumption of supplemental dietary car-
bohydrates is beneficial for health.
One explanation for this contradiction could be the accuracy 
of the detection methods employed to assess the composition 
of microbiota. The majority of these studies reveal difference 
on phylum or genus level, which fails to differentiate between 
commensal and opportunistic Clostridia. Indeed, studies 
assessing health effects of Clostridium that focus on the spe-
cies level reported high levels of opportunistic pathogens like 
Clostridium hathewayi and Clostridium ramosum to be linked 
to T2DM (106), whereas high weight loss was associated with 
a decrease in Clostridium coccoides and histolyticum (121, 122). 
In addition, Clostridium difficile is well known for its infectious 
properties, as it is an important cause of diarrhea in hospitalized 
patients (123). Finally, the presence of Clostridium septicum is 
suspected to play a role in colorectal carcinogenesis (124).
Altogether, there is no clear answer to the question how 
changes in Clostridium affect health, mainly because at the species 
level changes in abundance are known to have a great variety of 
effects. Moreover, the Clostridium genus includes species with 
a rather widespread evolutionary distribution, based on which 
this genus is not considered a phylogenetically coherent taxon 
(125). This high diversity in species within this genus makes it 
hard and possibly unreliable to identify health effects of the genus 
as a whole.
lACtoBACilluS
Merely increases in Lactobacilli abundance were reported by 
supplementation with disaccharides, oligosaccharides, and 
polysaccharides (73, 74, 76, 84, 91). In cases where changes in 
Bacteroidetes and Lactobacillus counts were found in the same 
study, their abundance increased, except for the study by Costabile 
et al. (84), where Lactobacillus enterococci abundance increased, 
whereas the Bacteroides and Prevotella counts decreased by 
supplementation of very long-chain inulin supplementation. In 
general, an increase in Lactobacillus abundance by supplemental 
dietary carbohydrates may be of potential interest since levels 
have been inversely associated with obesity (119, 122, 126). For 
example, the prevalence of the species Lactobacillus plantarum 
was higher in a group of lean versus obese individuals (76 versus 
27%, p = 0.005) (119). Weight loss in overweight adolescents due 
to a calorie-restricted diet and increased physical activity has 
been reported to be associated with an increase in Lactobacilli 
abundance (122). In addition, a study in obese rats showed that 
Lactobacillus abundance was increased upon controlled exercise 
training (i.e., which is often associated with weight loss) (126). 
Contradicting results have been mentioned too. Armougom et al. 
(96) observed significantly higher Lactobacillus species concen-
trations in adult obese subjects compared to lean ones. The same 
was recently reported for obese children (127). With qPCR as 
technique used in these studies, as well as in two out of three 
studies reporting an inverse relation between Lactobacillus and 
obesity, it is unlikely that the contradicting results are caused by 
differences in microbiota assessment.
A study by Karlsson et al. (105) in European women with nor-
mal, impaired, and diabetic glucose control revealed a positive 
association between Lactobacillus abundance and blood glucose 
levels by making use of metagenome-wide Illumina sequencing. 
Similar results were found in two qPCR studies in Japanese and 
Danish adults with T2DM, when compared to healthy individu-
als (116, 120). In addition, higher Lactobacillus abundance was 
found in participants diagnosed with MetS (23). These findings 
support the study by Armougom et al. (96) suggesting a positive 
association of high abundance of Lactobacilli with obesity and 
its implications.
There is nevertheless a plethora of studies showing that 
probiotic treatment (with or without supplemental dietary 
carbohydrates) with Lactobacilli strains could potentially be 
useful to combat obesity and cardiometabolic derangements. For 
instance, yogurt containing Lactobacilli led to decreased fasting 
plasma glucose and improved antioxidant status (and thus may 
have the potential to treat and/or prevent T2DM), which matches 
the previous studies in support of the benefits of increased 
Lactobacillus (128). Second, a study by Sanchez et al. in which 
capsules containing Lactobacillus rhamnosus and a mixture of 
inulin and oligofructose were ingested twice a day for a period 
of 24 weeks by obese women was able to cause better sustained 
weight maintenance after a period of weight loss than controls 
(129). Because of the fact that supplemental dietary carbohydrates 
often lead to an increase in Lactobacillus as well as in Bacteroides 
abundance, the latter effect may potentially abolish the positive 
effect of Lactobacillus.
BifidoBACtERium
Abundance of Bifidobacterium increased upon supplementation 
with disaccharides, oligosaccharides, and polysaccharides (64, 
73–75, 77–85, 88, 91). Supplementation with xylo-oligosaccharide 
seemed to have the highest feasibility, since only 1.4 g per day 
was found to be sufficient to increase Bifidobacterium abundance, 
with a treatment duration of 8 weeks (64). Xylo-oligosaccharide 
is naturally present in vegetables, fruits, milk, and honey, and can 
also be produced industrially (64).
The effects of the Bifidobacterium abundance on the host’s 
health have been well established. A study by Teixeira et  al. 
(119) investigated whether the abundance of specific microbes 
was associated with anthropometric, body composition, and 
biochemical measurements. The study was performed in 20 lean 
and 20 obese Brazilian women in their late twenties or early thir-
ties. Bifidobacterium genus counts were found to be significantly 
higher in lean women. In addition, Bifidobacteria abundance 
appeared to be inversely associated with insulin homeostasis 
model assessment (HOMA) index. The low abundance of 
Bifidobacteria in overweight adults and children, as well as in 
women gaining relatively much weight during pregnancy, has 
been reported in other studies as well (20, 101, 122, 130, 131). 
The inverse relation between Bifidobacteria abundance and 
diabetes was also found in a cohort study of 50 Chinese T2D 
patients compared to 30 healthy Chinese individuals (132). 
Comparable findings were reported in mice (133).
Plasma levels of bacterial lipopolysaccharide (LPS), a cell 
wall constituent of gram-negative bacteria with potent inflam-
matory actions (108), are inversely related to Bifidobacterium 
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abundance in the colon. Because chronic treatment with LPS 
in rodents is able to induce obesity and insulin resistance (134), 
there may be a course of events that link LPS, Bifidobacterium 
abundance, obesity, and inflammation (134, 135). The underly-
ing mechanism may lie in the fact that Bifidobacteria is known 
to be involved in the maintenance of the mucosal barrier 
(136, 137). Two possible scenarios may explain the link between 
Bifidobacterium loss and obesity and inflammation could be 
explained. Loss of Bifidobacterium may lead to higher transit 
of LPS and other bacterial fragments across the gut into sys-
temic circulation, resulting in a state of high plasma LPS. This 
state is referred to as metabolic endotoxemia and is frequently 
observed in obesity (20, 134). The second scenario is that this 
mechanism might be preceded by inflammation, which would 
enable certain members of the microbiota to survive the envi-
ronment, while others would not. These surviving members will 
mainly be pathobionts, resulting in a microbial dysbiosis leading 
to a washout of beneficial members like Bifidobacteria (138). 
A breach in the epithelial layer as a result of inflammation could 
subsequently lead to the transfer of LPS across the epithelial 
layer into the blood circulation, resulting in endotoxemia. Also 
other pathways exist that may not require LPS, which have been 
reviewed by others (139, 140).
Aside from the relation between Bifidobacterium counts and 
the prevalence of obesity, MetS, and T2DM, the potential of 
Bifidobacteria in the treatment of T2DM came to light more 
recently. A study by Tonucci et al. (141) in 50 Brazilian volun-
teers with T2DM (BMI <35 kg/m2, aged 35–60 years) revealed 
that treatment with fermented milk containing Bifidobacterium 
lactis and Lactobcillus acidophilus was able to improve glycemic 
control and decrease inflammatory markers. Similar find-
ings have been reported by other studies in humans as well 
(128, 142). In contrast to these findings, however, two studies 
in Estonia revealed a relation between higher Bifidobacterium 
abundance and higher blood glucose levels and occurrence 
of obesity in elderly and preschool children, respectively 
(143, 144). Bacteriological evaluation of the fecal samples in 
these studies, however, was based on manual counting of bac-
terial colony forming units on different agar plates, a method 
that is prone to errors (71, 145). Therefore, these contradicting 
conclusions are not highly reliable.
Overall, the effects of complex dietary supplemental carbohy-
drates to increase abundance of Bifidobacterium are useful since 
there is consensus that abundance of Bifidobacterium is lower in 
subjects who are obese and have cardiometabolic and/or inflam-
matory diseases.
AtoPoBium
The Atopobium genus was reported to be increased by disac-
charides and polysaccharides, with a treatment of 10–45.6 g a 
day for 2–3 weeks (73, 84). Very long-chain inulin was able to 
establish the increase within three weeks at a dose of 10 g a day, 
which seems a feasible dose (84). Atopobium is a genus belong-
ing to the class Actinobacteria, the class to which Bifidobacteria 
belongs to as well. How Atopobium is related to health is only 
reported in a limited number of studies, but all report favorable 
effects of higher Atopobium abundance. The genus is relatively 
unknown and only four studies were found investigating the 
relation of Atopobium to health. The first study by Sato et  al. 
(120) reported lower counts of the Atopobium cluster in 50 
Japanese T2DM patients, compared to 50 healthy individuals. 
This increase in Atopobium abundance could potentially play 
a role in the prevalence of T2DM. In addition, the study found 
a negative correlation of Atopobium abundance with levels 
of the inflammation marker hs-CRP and BMI, and a positive 
correlation with HDL cholesterol. These correlation all sup-
port the beneficial effects of increased Atopobium counts on 
cardiometabolic health. A second study by Maccaferri et  al. 
(146) investigated changes in the gut microbiota composition 
upon treatment with Rifaximin, a drug which is suggested to 
be able to induce clinical remission of active Crohn’s disease, 
which belongs to the cluster of IBDs. The study in an in vitro 
human colonic model system revealed that Atopobium levels 
were increased upon treatment, suggesting that increasing 
Atopobium could be part of the underlying mechanisms of the 
Rifaximin-induced reduction of inflammation of the bowel. 
Finally, Khachatryan et  al. (147) analyzed the composition of 
the gut microbiota in patients with familial Mediterranean fever 
(FMF), an auto-inflammatory disease characterized by recur-
rent self-resolving attacks of fever and polyserositis, followed 
by periods of remission without clinical signs. In that study, a 
trend was observed in which Atopobium was less abundant in 
the gut microbiota of FMF patients compared to healthy con-
trols, where abundance was lowest in attack and slightly higher 
during remission (42.2 counts per gram of fecal specimen for 
healthy individuals, 28.9 in remission, and 16.9 in attack, where 
this last value was significantly lower compared to the counts in 
healthy controls).
In conclusion, not many studies investigating the link between 
Atopobium abundance and cardiometabolic health are available, 
but the available ones discussed here do point in the direction of 
a beneficial effect of Atopobium abundance.
dESulfoviBRio
Desulfovibrio abundance was reported to be decreased by 
5.0 g of agave inulin intake per day for 21 days (83). Similar 
findings were reported in obese subjects supplemented with 
a mixture of galacto-oligosaccharides (148). In a Chinese 
cohort, this genus, that includes sulfate-reducing bacteria, 
has been reported to be increased in T2DM patients (106). In 
addition, a study in mice that were fed a diet supplemented 
with glycomacropeptide, a 64-amino acid glycophosphopep-
tide, showed that this diet reduced Desulfovibrio bacteria. This 
reduction was associated with decreased plasma concentra-
tions of the inflammation markers interferon-gamma, tumor 
necrosis factor-alpha, Interleukin-1beta, and Interleukin-2. 
These changes could contribute to the management of obe-
sity, IBD, and phenylketonuria (i.e., a disease due to impaired 
metabolism of the amino acid phenylalanine) (149). This find-
ing perhaps shares some grounds with the increased presence 
of Desulfovibrio species in patients suffering from ulcerative 
colitis, a type of IBD (150).
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The aforementioned studies are all in favor of the hypothesis 
that lowered Desulfovibrio abundance can benefit health. However, 
the one study by Karlsson et  al. (151) contradicts this because 
they reported lowered levels of Desulfovibrio in overweight and 
obese children in the age of 4–5  years, compared to children 
with a normal BMI. This contradiction might be age-related as 
the other studies investigating the Desulfovibrio abundance in 
humans all involved older participants.
THe CHOiCe OF SUPPLeMeNTAL 
FeRMeNTABLe CARBOHYDRATeS
Based on the data discussed above, it appears that dietary 
carbohydrate supplementation in healthy individuals seems to 
be associated with increases in the abundance of Bacteroides, 
Lactobacillus, Bifidobacterium, and Atopobium, whereas lower 
levels of abundance were generally observed in Clostridium and 
Desulfovibrio. With respect to the health effects of Bacteroides, 
there are discrepancies between obesity on the one hand and 
the cardiometabolic/inflammatory derangements that are often 
associated with it on the other hand. Thus, while both lower 
levels and higher levels of Bacteroides are reported to be found 
in obese individuals, higher levels seem to be associated primar-
ily with the occurrence of MetS, T2DM, and IBD, all derange-
ments known to involve increased activity of the inflammatory 
system (107–109). For this reason, it seems counterproductive 
to treat obese individuals, particularly those with MetS, and/
or related inflammatory diseases with dietary supplemental 
carbohydrates that would augment Bacteroides abundance. 
Dietary supplemental carbohydrates that do not increase the 
abundance of Bacteroides, but Bifidobacteria and potentially 
also Lactobacillus (although it is not yet clear about the latter 
whether it contributes to or protects against the onset of obesity, 
but see discussion on this subject below) instead, appear more 
helpful. Inulin, for example, may fulfill the above-mentioned 
criteria, as it increases Bifidobacteria abundance, and in some 
cases reduces Bacteroides abundance. Several papers show posi-
tive effects of inulin supplementation to reduce the severity of 
cardiometabolic and inflammatory derangements in obese and 
diabetic patients (42, 152). Also several animal studies point in 
this direction. For example, Rault-Nania et al. (153) showed that 
long-chain inulin supplementation in the diet of Wistar rats was 
able to reduce hypertriglyceridemia, hypertension, and heart 
peroxidation (i.e., increases in these are all signs of impaired 
cardiometabolic health) as a result of feeding a high fructose 
diet. Furthermore, mice exposed to a high-fat diet for 8 weeks 
with supplemental inulin (10%) or β-glucan (10%) had lower 
body weight gain relative to controls, with a lower energy intake 
observed in β-glucan supplemented mice than in inulin supple-
mented mice. In addition, the latter group showed reduced body 
fat content, but the former presented stronger hypothalamic 
neuronal effects. Fecal/cecal Bifidobacterium and Lactobacillus 
abundance was increased in both supplemental groups (154). 
The effect of inulin supplementation on cardiometabolic health 
was also assessed in gnotobiotic mice colonized with simplified 
human microbiota and challenged with a high-fat diet. Although 
the degree of obesity induction in these mice was comparable 
to control mice subjected to a high-fat diet, the inulin supple-
mented mice had increased bacterial diversity (including those 
of Bifidobacterium counts), significantly elevated concentra-
tions of total SCFA in cecum and portal vein plasma, signs of 
reduced lipogenesis, and an increased ratio of plasma and liver 
omega-3 versus omega-6 fatty acids (155). A very recent paper 
by Salazar et al. (156) indeed showed that inulin-type fructan 
supplementation of 16g/day over a 3-month period in 30 obese 
women (i.e., with maltodextrine as control treatment) caused 
significant fecal increases in several Bifidobacterium species, 
with Bifidobacterium longum being negatively correlated with 
serum LPS endotoxin levels. In addition, fasting insulinemia 
and HOMA index were significantly lower in the supplemented 
group than in the placebo group after the treatment period, 
albeit that SCFA, acetate and propionate concentrations also 
declined.
An important point that deserves more attention is the dose 
of the dietary carbohydrate supplementation needed to estab-
lish the alterations in gut microbiota, since some of the reported 
studies used doses of which long-term tolerability is question-
able. For example, a dose–response study by Bruhwyler et al. 
(157) showed that a dose of 20 g of inulin per day resulted in 
gastrointestinal complaints like flatulence. However, the cutoff 
of tolerability will likely differ per prebiotic and individual. Also 
the method of application may be of importance as it has been 
reported that soluble corn fiber is well tolerated up to 65 g/day, 
but only when consumed in multiple doses (158). Related to 
this point is the fact that none of the studies reporting on gut 
microbiota changes by supplemental carbohydrates assessed the 
regular dietary micro-/macronutrient and fiber composition of 
the participants. Since it is clear that the composition of the 
diet can affect the composition of the gut microbiota, this is a 
possible factor underlying the reported variability in responses 
and sometimes contradicting results between studies.
CONCLUSiON AND GAPS iN 
UNDeRSTANDiNG
Whereas it is relatively clear in which direction supplemental 
fermentable carbohydrates can alter the gut microbiome, the 
relevance of these changes regarding health remains controver-
sial. As already mentioned above, a clear exception is the genus 
Bifidobacterium, of which the benefits of an increased abun-
dance have been well established. Increases in Lactobacillus by 
dietary supplemental carbohydrates could potentially be health 
promoting as well (i.e., given the plethora of studies showing 
that probiotics that increase Lactobacilli generally can counter 
obesity and cardiometabolic diseases) but these effects may be 
counteracted by the stimulatory effects on Bacteroides abundance 
that often associates the effects on Lactobacillus. The controversy 
regarding Bacteroides and its role in obesity is also related to the 
discussion regarding the ratio between the phyla Bacteroidetes 
and Firmicutes, which has been reported to be related to obesity 
numerous times. However, the studies do not agree upon which 
of the phyla is the higher abundant phylum in obese individuals. 
The answer is still indefinite, indicating that it concerns a very 
complex matter of which not all the details are known yet. 
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Various health effects are reported at the species level, but the 
diversity of species within a genus makes that it is difficult to 
draw conclusions at the genus level. Therefore, there is a need 
for more comprehensive and species-specific characterization of 
the human microbiome. Studying the meta-transcriptome may 
be the most informative when linked also to either a species level 
picture of the microbiome or the genetic profile of the popula-
tion as a whole. The difficulty here of course is that we know the 
function of so few of the genes (i.e., not only what they mean for 
functioning of the specific bacteria but also for the host) but this 
knowledge is expected to grow quickly.
The majority of studies performed on obesity and micro-
biota ignore the fact that different causes of obesity should be 
taken into account. In short, maintenance of body weight is the 
result of a sustained match between energy intake and energy 
expenditure, and increased intake of energy-dense foods and/
or a decreased physical activity can logically underlie weight 
gain (94). Resistance to the adipocyte hormone leptin has been 
mentioned to be the resultant of the above-mentioned mismatch 
(159), or even the cause (140), which both could also explain the 
associated co-morbidities (160). Differences in energy-harvesting 
efficiency of microbiota (as a result of variation in its composi-
tion and abundance) can also play a role in the energy balance 
or imbalance herein, and the latter may contribute significantly 
to weight gain as well (2, 9, 94, 161, 162). As with recording of 
the habitual diet, also none of the studies reported in this review 
have assessed the energy budgets of the participants, which thus 
obstructs further insight into the contribution of energy absorp-
tion versus expenditure in the resultant body fat. Designing 
a study in which a large cohort of obese individuals with and 
without MetS (or related non-communicable diseases) is further 
divided into subgroups based on their energy budget, with one 
group having a more positive energy budget than the other, and 
subsequently investigate whether gut microbiota abundance and 
diversity between these subgroups differs at baseline would be 
of high relevance. Subsequent supplementation with dietary 
carbohydrates aiming to relief obesity and/or cardiometabolic/
inflammatory diseases should then include investigation of the 
entire energy balance equation in these individuals.
Weight gain in the form of increasing adiposity stores (i.e., 
which is a key risk factor to attract cardiometabolic and inflam-
matory health problems) is probably the result of selective or 
evolutionary pressures that have shaped our paleolithic (or even 
earlier) ancestors to deal with food shortages. This theory was first 
hypothesized by Neel to explain the current epidemic of diabetes 
(163), and was later expanded toward the epidemic of obesity [see 
Ref. (164) as an example]. The above-mentioned evolutionary 
pressure probably also co-shaped the gut microbiome (165, 166). 
To this end, it is of interest to consider the possibility that the gut 
microbiota affects the hosts’ (and therefor its own) energy balance 
to increase the chances of survival in times of famine by offering 
ample nutrients from otherwise indigestible food ingredients, 
but also—via the microbiota-gut-brain axis—to affect the host’s 
eating behavior, hunger/satiety, and even reward and mood 
aspects of food, to stimulate food searching, craving, etc. (167). In 
our current western-industrialized society, where industrialized 
and processed foods are highly abundant, but contain relatively 
little amounts of fibers, this may underlie a conflict between host 
and microbiota leading to increased craving as well (167). Recent 
findings in line with this hypothesis are reported by Perry et al. 
(168). This study in rats revealed that exposure to a calorically 
dense high-fat diet resulted in increased ghrelin secretion and 
glucose-stimulated insulin secretion, which may promote hyper-
phagia and increased energy storage as fat. The reported changes 
were found to be the result of an altered gut microbiota, acting 
through the parasympathetic nervous system. For this reason, 
a primal or ancestral diet, which contains in itself many of the 
complex carbohydrates with prebiotic properties as discussed 
in this review, should be promoted more rigorously in order to 
prevent obesity and cardiometabolic/inflammatory diseases [e.g., 
by restoring leptin sensitivity (140)]. These sorts of mechanisms 
are of interest from an “evolutionary medicine” point of view, and 
should certainly be taken into account to fully understand the 
role of the microbiome in health and disease.
FUTURe DiReCTiONS
Although there is consensus that supplemental dietary car-
bohydrates have the tendency to increase the abundance of 
Bifidobacterium, Bacteroides, Lactobacilli, and Atopobium and to 
decrease the abundance of Clostridium and Desulfovibrio in the 
human gut, it remains unclear whether specific types of ferment-
able carbohydrates target specific bacterial groups, or whether a 
change in abundance of one group would influence the rest of the 
community through cross feeding. That being said, the definition 
of prebiotics as it is currently used—“non-digestible food ingredi-
ents that beneficially affect the host by selectively stimulating the 
growth and/or activity of one or a limited number of bacterial spe-
cies already resident in the colon, in the attempt to improve host 
health” (36)—might need revision. The stimulation of beneficial 
bacterial species might in fact be mediated by or coincided with 
a decrease or increase in abundance of a species with undeter-
mined health effects. Therefore, a suggested alternative definition 
of prebiotics would be “non-digestible food ingredients that affect 
the host by selectively stimulating or inhibiting the growth and/
or activity of one or a limited number of bacterial species already 
resident in the colon, with the net effect of the microbial change 
being beneficial for the host’s health.” It might not be reliable to 
generalize the effects of prebiotics since this will likely depend 
on the host genotype, current health status, and susceptibility 
to disease (169). How then alterations in gut microbiota exactly 
influence the host’s health remains largely undetermined, but 
several mechanisms may contribute as already explained in the 
previous parts of this review and elsewhere (140, 170).
The gut microbiota carry out a wide range of biotransforma-
tion reactions during metabolism of the diet, including those 
that are not present in the mammalian host (171). This provides 
an important way to further investigate the effect of changes 
in the gut microbiota, established by prebiotics, on the host’s 
health, i.e., by means of investigating the microbiota-dependent 
metabolites. Trimethylamine, for example, is the product of 
microbiota-dependent choline (essential dietary nutrient) 
metabolism (172). A potential link between the intestinal 
microbiota, dietary choline, and CVD risk has been suggested, 
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where increased metabolites of the dietary lipid phosphatidyl-
choline have been observed in the serum of patients with CVD 
pathogenesis (19, 173, 174). This makes that these metabolites 
are potential measures to assess health effects of changes in 
microbial genera discussed in this review, but applicability and 
reliability of this measure must be elucidated first. This research 
area of mass spectrometry identified signatures is quickly 
expanding and candidate metabolite factors are increasingly 
identified with notable bioactivities (175). With the current 
knowledge, however, it remains hard to determine whether 
alterations in gut microbiota and/or their metabolites are cause 
or consequence of cardiometabolic/inflammatory diseases. 
Thus, while it has been confirmed that obesity, MetS, T2DM, 
and CVD are usually associated with chronic inflammation 
(176) and convincing evidence links the gut microbiome to 
inflammation (177–179), future research should focus on 
whether, how and to what extent mechanisms of inflammation 
and beyond are indeed bidirectional between the host and the 
microbiome. This requires system biological approaches and 
“big-data” analysis combined with in depth analysis of the effect 
of targeted perturbations in microbiota as well as in the host. 
Refined studies on the effects of reconstitution of microbiota 
in gnotobiotic mouse systems may be important for unraveling 
some of these interactions. Human intestinal organoids (i.e., 
near physiological 3D models of the human gut grown from 
human stem cells) appear to have great potential for studying 
these interactions as well (180) and eventually may take this to 
a “personalized” therapeutic level (181), from the perspective of 
both the host and the microbiome.
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